Phase II study of chemotherapy with Capecitabine/Bevacizumab in elderly patients with advanced and recurrent colorectal cancer
- Conditions
- advanced and/or recurrent colorectal cancer
- Registration Number
- JPRN-UMIN000010200
- Lead Sponsor
- Yamafuchi University Medical Bioregulation Department of Organ Regulatory Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Not provided
(1)active brain metastases (2) Complication of cerebrovascular disease or symptoms within 1 year (3) Patient receiving surgical procedure or such as skin-open biopsy, trauma surgery, or other more intensive surgeries within 4 weeks or aspiration biopsy within a week (4) History of gastrointestinal perforation within 1 year. (5) Uncontrollable peptic ulcer, Hypertension, diarrhea, infections (6) A bleeding tendency, coagulation disorder or abnormal coagulation factor (7) bleeding diathesis or receiving anticoagulant drug(except Aspirin under 325mg/day) (8) Serious heart disease (9) History of active double cancer within 5 years (10)History of the serious hypersensitivity for capecitabine or bevacizumab (11)Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method